US · OCUL
Ocular Therapeutix, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Bedford, MA 01730
- Website
- ocutx.com
Price · as of 2025-12-31
$9.43
Market cap 1.95B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.07 | +197.67% |
| Intrinsic Value(DCF) | $5.48 | -41.89% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $13.72 | +45.5% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $42.95 | $11.07 | $0.00 | ||
| 2015 | $8.43 | $37.78 | $3.04 | $0.00 | $0.00 |
| 2016 | $8.47 | $24.59 | $1.47 | $0.00 | $0.00 |
| 2017 | $5.90 | $19.31 | $0.00 | $0.00 | $0.00 |
| 2018 | $4.29 | $23.73 | $0.00 | $0.00 | $0.00 |
| 2019 | $6.91 | $34.30 | $279.58 | $0.00 | $0.00 |
| 2020 | $20.84 | $55.72 | $244,297.84 | $0.00 | $0.00 |
| 2021 | $5.31 | $67.17 | $8,929,284.02 | $0.72 | $0.00 |
| 2022 | $4.87 | $40.06 | $124,554.23 | $0.00 | $0.00 |
| 2023 | $9.98 | $42.47 | $49.12 | $0.00 | $0.00 |
| 2024 | $7.54 | $25.62 | $0.82 | $0.00 | $0.00 |
| 2025 | $10.98 | $28.07 | $1.82 | $0.00 | $13.72 |
AI valuation
Our deep-learning model estimates Ocular Therapeutix, Inc.'s (OCUL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.07
- Current price
- $9.43
- AI upside
- +197.67%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.48
-41.89% upside
Graham-Dodd
—
— upside
Graham Formula
$13.72
+45.5% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OCUL | Ocular Therapeutix, Inc. | $9.43 | 1.95B | +198% | -42% | — | +46% | -7.73 | 3.14 | 39.67 | -5.60 | -47.16 | 3.14 | 87.31% | -521.04% | -513.17% | -54.85% | 13699.49% | -42.01% | 0.12 | -22.82 | 15.39 | 15.11 | 2.63 | 1639.00% | -1867.00% | 5952.00% | -10.55% | -4.03 | 11004.21% | 0.00% | 0.00% | 16.58% | -5.18 | -6.45 | 26.99 | 6.07 |
| COGT | Cogent Biosciences, Inc. | $38.85 | 6.31B | — | — | — | — | -7.99 | 4.13 | — | -6.03 | -218.46 | 4.13 | 0.00% | — | — | -73.70% | 2714.02% | -51.99% | 0.40 | -108.87 | 14.23 | 14.08 | 0.18 | 366.00% | — | 2766.00% | -10.12% | -4.13 | 2165.58% | 0.00% | 0.00% | 0.00% | -5.94 | -7.45 | — | 3.37 |
| EWTX | Edgewise Therapeutics, In… | $30.44 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| GLPG | Galapagos N.V. | $33.66 | 2.22B | +251% | +430,280% | +154% | +4,930% | 6.01 | 0.60 | 1.73 | -1.90 | 1.80 | 0.60 | 93.49% | 40.56% | 28.85% | 10.47% | 2205.83% | 8.51% | 0.00 | 164.04 | 20.15 | 19.95 | -0.14 | 33304.00% | 30348.00% | -4967.00% | -10.50% | -1.24 | -989.65% | 0.00% | 0.00% | 1.20% | -2.34 | 5.22 | -0.95 | 8.66 |
| GPCR | Structure Therapeutics In… | $62.98 | 3.63B | — | — | — | — | -26.37 | 2.46 | — | -16.39 | -1028.46 | 2.46 | 0.00% | — | — | -11.86% | -570.89% | -11.35% | 0.00 | — | 24.81 | 22.85 | 5.69 | 256.00% | — | 9149.00% | -6.06% | -3.51 | -730.15% | 0.00% | 0.00% | 16.85% | -12.94 | -10.11 | — | 33.44 |
| IBRX | ImmunityBio, Inc. | $9.78 | 9.63B | +901% | -57% | — | — | — | -19.22 | 84.77 | -45.80 | — | -18.70 | 99.34% | -226.00% | -310.18% | 0.00% | -52123.97% | 0.00% | -1.76 | -2.28 | 5.10 | 4.62 | -3.53 | -3871.00% | 66831.00% | -2341.00% | -3.18% | -4.94 | -62105.09% | 0.00% | — | 0.00% | -39.99 | -33.58 | 90.38 | -5.49 |
| LQDA | Liquidia Corporation | $31.02 | 2.7B | -15% | +1,142% | — | -41% | -8.95 | 15.09 | 83.34 | -9.61 | -24.05 | 16.61 | 58.00% | -866.63% | -931.65% | -209.35% | -667.62% | -74.80% | 1.58 | -9.71 | 4.43 | 4.29 | 0.47 | 3719.00% | -1997.00% | 12955.00% | -8.43% | -2.24 | -541.45% | 0.00% | 0.00% | 1.71% | -9.17 | -11.31 | 79.48 | 0.24 |
| MESO | Mesoblast Limited | $15.85 | 2.04B | +203% | -57% | — | — | -17.02 | 2.91 | 101.06 | -23.15 | — | 67.85 | 70.17% | -363.08% | -593.92% | -18.95% | -11.34% | -14.05% | 0.21 | -2.72 | 1.99 | 1.72 | 0.45 | -562.00% | 19139.00% | 388.00% | -2.92% | -0.49 | -9.21% | 0.00% | 0.00% | 5.14% | -27.31 | -33.64 | 99.14 | 3.68 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| RCUS | Arcus Biosciences, Inc. | $20.37 | 2.05B | +8% | -43% | — | — | -7.28 | 4.07 | 10.41 | -5.04 | -152.47 | 4.07 | 95.95% | -156.28% | -142.91% | -63.26% | 112.87% | -30.84% | 0.16 | -48.25 | 4.36 | 4.25 | 0.37 | 478.00% | -426.00% | 17500.00% | -18.82% | -2.09 | 141.52% | 0.00% | 0.00% | 1.28% | -4.38 | -3.49 | 6.84 | 1.13 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- CEO
- Pravin U. Dugel
- Employees
- 274
- Beta
- 0.90
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.48 ÷ $9.43) − 1 = -41.89% (DCF, example).